CNET on MSN6d
GLP-1 Meds Like Ozempic: Know Potential Benefits, Risk Factors and Overdose Info
Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...
News-Medical.Net on MSN4d
GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients
Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...
pharmaphorum3d
Roche reveals first data with Carmot-sourced oral GLP-1 drug
Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of ... were "consistent with the safety profile of the incretin drug class," and will now progress to ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Medical Marketing & Media15h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...